AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23243282
Drug: Pomalidomide 4
RxNorm normalized name: pomalidomide 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 4 mg per day on days 1 to 21 of each 28-day cycle
Trial: 23243282
Drug: Pomalidomide 4
RxNorm normalized name: pomalidomide 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 4 mg per day with dexamethasone 40 mg per week
Trial: 23243282
Drug: Pomalidomide 4
RxNorm normalized name: pomalidomide 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 4 mg per day
Trial: 23243282
Drug: Dexamethasone 40
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 40 mg per week
Trial: 23245284
Drug: Conformal or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conformal or intensity modulated radiation therapy
Trial: 23247661
Drug: R-CHOEP-14 followed
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOEP-14 followed by high-dose cytarabine and high-dose methotrexate
Trial: 23248254
Drug: Bendamustine 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine 120 mg/m² as a 30-minute infusion on days 1 and 2 every 28 days with growth factor support
Trial: 23248257
Drug: Trametinib (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib (2 mg orally once daily) in cohort A
Trial: 23248257
Drug: Trametinib (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib (2 mg orally once daily) in cohort B
Trial: 23249699
Drug: Levothyroxine (T4)
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (T4) treatment
Trial: 23250892
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml kg(-1) colloid for 10 min
Trial: 23250963
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CSF TT and Rout
Trial: 23253635
Drug: Tapentadol vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol vs Oxycodone
Trial: 23254596
Drug: Amlodipine/Olmesartan (AML/OM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/Olmesartan (AML/OM) 5/20 mg for 4 weeks, followed by uptitration to AML/OM 5/40 mg, AML/OM 10/40 mg, AML/OM 10/40 mg + HCTZ 12.5 mg, and AML/OM 10/40 mg + HCTZ 25 mg at 4-week intervals if BP remained uncontrolled.
Trial: 23255310
Drug: Hydroxyurea at
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea at maximum tolerated dose (MTD, 24.4 ± 4.5 mg/kg/day, range 15.3-30.6 mg/kg/day)
Trial: 23256542
Drug: 17-allyamino-17-demethoxygeldanamycin (17-AAG)
RxNorm normalized name: 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-allyamino-17-demethoxygeldanamycin (17-AAG) 150 mg/m(2) and bortezomib 0.7 mg/m(2)
Trial: 23256542
Drug: 17-allyamino-17-demethoxygeldanamycin (17-AAG)
RxNorm normalized name: 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-allyamino-17-demethoxygeldanamycin (17-AAG) in combination with bortezomib
Trial: 23256542
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 17-AAG and bortezomib
Trial: 23259667
Drug: Docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (100 mg/m², 3qw, 6 courses)
Trial: 23259667
Drug: DTC-status before
RxNorm normalized name: Statuss Green Reformulated Jan 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTC-status before and after docetaxel treatment
Trial: 23261356
Drug: Selumetinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (50 mg twice daily, orally) until progression
Trial: 23265285
Drug: Albuterol sulfate
RxNorm normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol sulfate hydrofluoroalkane (HFA) metered-dose inhaler with integrated dose counter, 90 micrograms, twice-daily dosing for 5 or 7 weeks
Trial: 23265712
Drug: Intravenous bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous bevacizumab (5mg/kg every 14 days) and oral rapamycin (1-6 mg/day)
Trial: 23267529
Drug: Telehealth problem-solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth problem-solving therapy (PST)
Trial: 23269537
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg/day on a continuous daily dosing (CDD) schedule
Trial: 23269861
Drug: Prucalopride 2
RxNorm normalized name: prucalopride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride 2 mg (single oral dose)
Trial: 23269986
Drug: Adjuvant procarbazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy
Trial: 23270487
Drug: Miglustat 100
RxNorm normalized name: miglustat 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglustat 100 mg t.i.d.
Trial: 23270493
Drug: Sitagliptin 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 600 mg orally days -1 to +2
Trial: 23272643
Drug: Diammine silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diammine silver fluoride (DSF) applied to 3 teeth, mean amount 7.57 mg (6.04 μL)
Trial: 23273522
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/day and bevacizumab 15 mg/kg every 3 weeks until progression
Trial: 23274395
Drug: Liposomal-encapsulated docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal-encapsulated docetaxel (LE-DT) at 132 mg/m(2)
Trial: 23274395
Drug: Liposomal-encapsulated docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal-encapsulated docetaxel (LE-DT) at 110 mg/m(2)
Trial: 23274395
Drug: Liposomal-encapsulated docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal-encapsulated docetaxel (LE-DT) at 85 mg/m(2)
Trial: 23274902
Drug: Posttransplant antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posttransplant antibody increase (DSA or autoantibodies)
Trial: 23274902
Drug: No posttransplant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No posttransplant antibody increase
Trial: 23274906
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of [6,6-²H₂]-glucose followed by ingestion of four eggs containing 23 g of labeled proteins
Trial: 23277518
Drug: Volatile organic
RxNorm normalized name: coal tar pitch volatiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volatile organic compounds (VOCs) in exhaled breath
Trial: 23278639
Drug: Denileukin diftitox
RxNorm normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Denileukin diftitox (DD) 18 μg/kg/day (days 1, 2) with CHOP (day 3) every 21 days for ≤ 6-8 cycles
Trial: 23281876
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR 300-800 mg once daily
Trial: 23281975
Drug: ABT-450/r (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-450/r (250 mg ABT-450 + 100 mg ritonavir) + ABT-333 (400 mg twice daily) + ribavirin (1000 to 1200 mg per day)
Trial: 23281975
Drug: ABT-450/r (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-450/r (150 mg ABT-450 + 100 mg ritonavir) + ABT-333 (400 mg twice daily) + ribavirin (1000 to 1200 mg per day)
Trial: 23283106
Drug: Standard curative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard curative whole gland therapy
Trial: 23285253
Drug: Boosted protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boosted protease inhibitors (PI/r)
Trial: 23286772
Drug: MTX and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX and anti-TNF treatment
Trial: 23287861
Drug: Panobinostat at
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat at 30 mg 3 times a week (12 of 36 patients at 25 mg dose)
Trial: 23288588
Drug: Low-dose IFN-α
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IFN-α therapy
Trial: 23288588
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no IFN-α treatment)
Trial: 23289822
Drug: Once-daily insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily insulin detemir (Group A)
Trial: 23289822
Drug: Twice-daily insulin
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily insulin detemir (Group B)
Trial: 23291945
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of PHiD-CV
Trial: 23292236
Drug: BU pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BU pharmacokinetics (PKs) in patients with GSTM1 null genotype
Trial: 23292236
Drug: Gene-dosage effect
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene-dosage effect
Trial: 23292756
Drug: BMI, leptin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMI, leptin, L/A ratio and CA 15-3
Trial: 23299114
Drug: Broad-spectrum antibiotics
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum antibiotics (including macrolide antibiotics and penicillin V)
Trial: 23299114
Drug: GPs with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPs with a prescription rate of 33.3% or higher
Trial: 23299315
Drug: BiRd therapy
RxNorm normalized name: Bird pepper
DrugBank: Bird pepper (DB14262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BiRd therapy (clarithromycin 500 mg twice daily, lenalidomide 25 mg daily on days 1 to 21 of a 28-day cycle, dexamethasone 40 mg weekly)
Trial: 23299315
Drug: BiRd therapy
RxNorm normalized name: Bird pepper
DrugBank: Bird pepper (DB14262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BiRd therapy
Trial: 23299770
Drug: CF102 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF102 (1, 5, and 25 mg BID)
Trial: 23302513
Drug: Hatha yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hatha yoga classes (2 weekly 60-minute sessions for 32 weeks)
Trial: 23303450
Drug: STAT3 peptide
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAT3 peptide inhibitor
Trial: 23303512
Drug: Individual Burden
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual Burden of Illness Index for Depression (IBI-D) after 12-week citalopram treatment
Trial: 23305037
Drug: Glimepiride treatment
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride treatment (1 mg/d, titrated to 2 mg/d and 4 mg/d)
Trial: 23305475
Drug: Insulin analogues
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin analogues (insulin aspart, insulin detemir, biphasic insulin aspart 30)
Trial: 23307766
Drug: Antivirals administered
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antivirals administered to 1041 (58%) patients; treatment was at the physician's discretion.
Trial: 23314553
Drug: Copeptin ultra-sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copeptin ultra-sensitive (copeptin-us) ≥14 pmol/L and hs-cTnT ≥0.014 µg/L
Trial: 23314553
Drug: Copeptin ultra-sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copeptin ultra-sensitive (copeptin-us) <14 pmol/L and hs-cTnT <0.014 µg/L
Trial: 23314553
Drug: hs-cTnT ≥0.014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT ≥0.014 µg/L alone
Trial: 23314553
Drug: Copeptin ultra-sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copeptin ultra-sensitive (copeptin-us) ≥14 pmol/L added to hs-cTnT
Trial: 23315343
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid (75-325 mg)
Trial: 23315343
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid experienced patients
Trial: 23315343
Drug: Low-dose acetylsalicylic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acetylsalicylic acid naïve patients
Trial: 23315905
Drug: Deficient 25(OH)D
RxNorm normalized name: vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deficient 25(OH)D levels (<30 nmol/L)
Trial: 23315905
Drug: Inadequate 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inadequate 25(OH)D levels (30-49.9 nmol/L)
Trial: 23315905
Drug: High 25(OH)D
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High 25(OH)D levels (>100 nmol/L)
Trial: 23316779
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of CA4P at a dose of 27 or 36 mg/m2 for 4 consecutive weeks
Trial: 23316779
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of CA4P
Trial: 23318482
Drug: Lesogaberan (AZD3355)
RxNorm normalized name: Lesogaberan
DrugBank: Lesogaberan (DB11920)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesogaberan (AZD3355) as an add-on to PPI therapy
Trial: 23320604
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose [90Y-DOTA]-TOC (median: 2.4 GBq/cycle)
Trial: 23320604
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose [90Y-DOTA]-TOC (median: 3.3 GBq/cycle)
Trial: 23320604
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose [90Y-DOTA]-TOC (median: 6.7 GBq/cycle)
Trial: 23320927
Drug: huKS-IL2 (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: huKS-IL2 (3.0 mg/m2 IV continuous infusion over 4 hours on days 2, 3, and 4) with cyclophosphamide (300 mg/m2 on day 1)
Trial: 23320927
Drug: huKS-IL2 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: huKS-IL2 (various doses) with cyclophosphamide (300 mg/m2)
Trial: 23321252
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of YM155 and alemtuzumab
Trial: 23321953
Drug: RAD001 (everolimus)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RAD001 (everolimus) 70 mg administered orally on days 1 and 7 of a 3+7 daunorubicin+cytarabine chemotherapy regimen
Trial: 23321953
Drug: RAD001 (everolimus)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RAD001 (everolimus) 70 mg
Trial: 23325012
Drug: Once-monthly pegylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-monthly pegylated epoetin Beta
Trial: 23325902
Drug: Everolimus (oral),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (oral), starting at 3 mg/m2 per day, titrated to achieve trough concentrations of 5-15 ng/mL.
Trial: 23325915
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of 2% nonoxynol-9 (N-9) gel
Trial: 23325915
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of Normosol-R fluid alone (negative control)
Trial: 23325915
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of Normosol-R with coital simulation and sigmoidoscopic biopsy (CS + BX)
Trial: 23325920
Drug: L-lysine from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-lysine from cooked white rice (CWR) at doses of 10, 15, and 19 mg·kg(-1)·d(-1)
Trial: 23325920
Drug: L-lysine from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-lysine from oven-browned cooked rice at a dose of 19 mg·kg(-1)·d(-1)
Trial: 23327295
Drug: Haloperidol prophylaxis
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol prophylaxis (1 mg/8 h)
Trial: 23328269
Drug: Continuation maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation maintenance pemetrexed therapy plus best supportive care (BSC)
Trial: 23329066
Drug: AZD4877 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4877 25 mg administered once-weekly for 3 weeks of each 4-week cycle until disease progression, death, unacceptable toxicity or withdrawal
Trial: 23329066
Drug: AZD4877 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4877 25 mg
Trial: 23331739
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.1% ointment once daily for 12 weeks
Trial: 23331739
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.1% ointment continued in open label extension for relapsing patients
Trial: 23331739
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.1% ointment for perineal disease
Trial: 23331739
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.1% ointment overall safety
Trial: 23332165
Drug: Drug-eluting absorbable
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting absorbable metal scaffold (DREAMS)
Trial: 23333219
Drug: TNF-α antagonists
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TNF-α antagonists (infliximab, etanercept, adalimumab)
Trial: 23335740
Drug: Caspofungin 70
RxNorm normalized name: caspofungin 70 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin 70 mg QD
Trial: 23335740
Drug: Caspofungin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin 100 mg QD
Trial: 23335740
Drug: Caspofungin 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin 150 mg QD
Trial: 23335740
Drug: Caspofungin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin 200 mg QD
Trial: 23340184
Drug: Visible cerebral
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visible cerebral NIRS oximetry with pre-specified treatment guidelines
Trial: 23340271
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical therapies (CMTs)
Trial: 23341526
Drug: Erlotinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib plus whole-brain radiation therapy (WBRT)
Trial: 23343427
Drug: Moxifloxacin (Avelox®)
RxNorm normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (Avelox®) 400 mg once daily for a mean duration of 6.4 ± 1.9 days
Trial: 23344123
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving neuromuscular block reversal agents (66.6% of patients; neostigmine in 97%)
Trial: 23344123
Drug: Patients not
RxNorm normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not receiving neuromuscular block reversal agents
Trial: 23344286
Drug: Pravastatin (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (dosage and duration not specified)
Trial: 23348202
Drug: i.v. fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. fluid (15 ml kg(-1) in 30 min)
Trial: 23348203
Drug: Subgluteal sciatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgluteal sciatic nerve block with 20 ml of ropivacaine 4.75 mg ml(-1)
Trial: 23349326
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow-derived mesenchymal stromal cells (MSCs) - 1 million cells per kilogram, two intravenous infusions
Trial: 23352199
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of valproate